Copy number analysis of ductal carcinoma in situ with and without recurrence

Modern Pathology

Volumn 28, Issue 9, 2015, Pages 1174-1184

  Gorringe, Kylie L ^a,b,c   Hunter, Sally M ^a   Pang, Jia Min ^a   Opeskin, Ken ^d   Hill, Prue ^d   Rowley, Simone M ^a   Choong, David Y H ^a   Thompson, Ella R ^a,b,c   Dobrovic, Alexander ^b,e   Fox, Stephen B ^a   Mann, G Bruce ^c,f   Campbell, Ian G ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^f ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE AMPLIFICATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR INVASION; WIDE EXCISION; AGED; BREAST TUMOR; DNA MICROARRAY; GENE DOSAGE; GENETICS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POLYMERASE CHAIN REACTION; TUMOR RECURRENCE;

AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION;

EID: 84940651094     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.75     Document Type: Article

References (43)

1. Sanders ME, Schuyler PA, Dupont WD et al. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103: 2481-2484.
2. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M et al. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 2010;57: 171-192.
3. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004; 96:906-920.
4. Benson JR, Wishart GC. Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. Lancet Oncol 2013;14:e348-e357.
5. Boxer MM, Delaney GP, Chua BH. A review of the management of ductal carcinoma in situ following breast conserving surgery. Breast 2013;22:1019-1025.
6. Donker M, Litiere S, Werutsky G et al. Breastconserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 2013;31: 4054-4059.
7. Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 2006;3:621-632.
8. Ciriello G, Miller ML, Aksoy BA et al. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013;45:1127-1133.
9. Liao S, Desouki MM, Gaile DP et al. Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast. Genes Chromosomes Cancer 2012;51:1067-1078.
10. Johnson CE, Gorringe KL, Thompson ER et al. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma. Breast Cancer Res Treat 2012;133:889-898.
11. Hernandez L, Wilkerson PM, Lambros MB et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol 2012;227:42-52.
12. Allred DC, Clark GM, Molina R et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992;23:974-979.
13. Tamimi RM, Baer HJ, Marotti J et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008; 10:R67.
14. Gao Y, Niu Y, Wang X et al. Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. J Mol Med 2009;87: 145-152.
15. Fong J, Kurniawan ED, Rose AK et al. Outcomes of screening-detected ductal carcinoma in situ treated with wide excision alone. Ann Surg Oncol 2011;18: 3778-3784.
16. Wang Y, Moorhead M, Karlin-Neumann G et al. Analysis of molecular inversion probe performance for allele copy number determination. Genome Biol 2007;8:R246.
17. Brewster AM, Thompson P, Sahin AA et al. Copy number imbalances between screen-and symptomdetected breast cancers and impact on disease-free survival. Cancer Prev Res (Phila) 2011;4:1609-1616.
18. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
19. Curtis C, Shah SP, Chin SF et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012;486:346-352.
20. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
21. Van Loo P, Nordgard SH, Lingjaerde OC et al. Allelespecific copy number analysis of tumors. Proc Natl Acad Sci USA 2010;107:16910-16915.
22. Buerger H, Otterbach F, Simon R et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 1999;187:396-402.
23. Hwang ES, DeVries S, Chew KL et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 2004;10:5160-5167.
24. Vos CB, ter Haar NT, Rosenberg C et al. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer 1999;81:1410-1418.
25. Kerlikowske K, Molinaro AM, Gauthier ML et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010;102:627-637.
26. Rakovitch E, Nofech-Mozes S, Hanna W et al. HER2/ neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2012;106:1160-1165.
27. Waldman FM, DeVries S, Chew KL et al. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst 2000;92:313-320.
28. Littlepage LE, Adler AS, Kouros-Mehr H et al. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov 2012;2:638-651.
29. Nonet GH, Stampfer MR, Chin K et al. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 2001;61:1250-1254.
30. Anzick SL, Kononen J, Walker RL et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-968.
31. Garcia-Murillas I, Sharpe R, Pearson A et al. An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer. Oncogene 2014;33: 2478-2486.
32. Zhou H, Kuang J, Zhong L et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-193.
33. Usary J, Llaca V, Karaca G et al. Mutation of GATA3 in human breast tumors. Oncogene 2004;23: 7669-7678.
34. Jin W, Kim GM, Kim MS et al. TrkC plays an essential role in breast tumor growth and metastasis. Carcinogenesis 2010;31:1939-1947.
35. Ory V, Tassi E, Cavalli LR et al. The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ. Oncogene 2014;33:3033-3042.
36. Hwang ES, Lal A, Chen YY et al. Genomic alterations and phenotype of large compared to small highgrade ductal carcinoma in situ. Hum Pathol 2011;42: 1467-1475.
37. Wang ZC, Birkbak NJ, Culhane AC et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012;18: 5806-5815.
38. Birkbak NJ, Eklund AC, Li Q et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011;71: 3447-3452.
39. Auer GU, Caspersson TO, Wallgren AS. DNA content and survival in mammary carcinoma. Anal Quant Cytol 1980;2:161-165.
40. Kronenwett U, Ploner A, Zetterberg A et al. Genomic instability and prognosis in breast carcinomas. Cancer Epidemiol Biomarkers Prev 2006;15:1630-1635.
41. Hicks J, Krasnitz A, Lakshmi B et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006;16: 1465-1479.
42. Generali D, Buffa FM, Deb S et al. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. Br J Cancer 2014;111:46-54.
43. Zhou W, Jirstrom K, Amini RM et al. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: A population-based cohort study. BMC Cancer 2013;13:512.